[go: up one dir, main page]

BRPI0818937B8 - constructos contendo múltiplos cassetes de expressão para terapia de câncer - Google Patents

constructos contendo múltiplos cassetes de expressão para terapia de câncer

Info

Publication number
BRPI0818937B8
BRPI0818937B8 BRPI0818937A BRPI0818937A BRPI0818937B8 BR PI0818937 B8 BRPI0818937 B8 BR PI0818937B8 BR PI0818937 A BRPI0818937 A BR PI0818937A BR PI0818937 A BRPI0818937 A BR PI0818937A BR PI0818937 B8 BRPI0818937 B8 BR PI0818937B8
Authority
BR
Brazil
Prior art keywords
containing multiple
cancer therapy
expression cassettes
constructs containing
multiple expression
Prior art date
Application number
BRPI0818937A
Other languages
English (en)
Inventor
Hochberg Avraham
Amit Doron
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Publication of BRPI0818937A2 publication Critical patent/BRPI0818937A2/pt
Publication of BRPI0818937B1 publication Critical patent/BRPI0818937B1/pt
Publication of BRPI0818937B8 publication Critical patent/BRPI0818937B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

constructos contendo múltiplos cassetes de expressão para terapia de câncer. a presente invenção se refere ao campo de tratamento de câncer, particularmente a novos constructos úteis para o tratamento de tumores expressando h19 e/ou igf-ii. mais especificamente, a invenção fornece composições e métodos que utilizam um constructo de ácido nucleico que permite a expressão de um produto gênico citotóxico por mais de um promotor tumor-específico.
BRPI0818937A 2007-10-25 2008-10-23 constructos contendo múltiplos cassetes de expressão para terapia de câncer BRPI0818937B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98244207P 2007-10-25 2007-10-25
PCT/IL2008/001405 WO2009053982A1 (en) 2007-10-25 2008-10-23 Constructs containing multiple expression cassettes for cancer therapy

Publications (3)

Publication Number Publication Date
BRPI0818937A2 BRPI0818937A2 (pt) 2016-10-11
BRPI0818937B1 BRPI0818937B1 (pt) 2019-11-26
BRPI0818937B8 true BRPI0818937B8 (pt) 2021-05-25

Family

ID=40266127

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818937A BRPI0818937B8 (pt) 2007-10-25 2008-10-23 constructos contendo múltiplos cassetes de expressão para terapia de câncer

Country Status (14)

Country Link
US (2) US9173964B2 (pt)
EP (1) EP2203187B1 (pt)
JP (1) JP5486502B2 (pt)
KR (1) KR101539796B1 (pt)
CN (1) CN101903046B (pt)
AU (1) AU2008315409B2 (pt)
BR (1) BRPI0818937B8 (pt)
CA (1) CA2703774C (pt)
CY (1) CY1113659T1 (pt)
ES (1) ES2394129T3 (pt)
IL (1) IL205048A (pt)
RU (1) RU2487165C2 (pt)
SI (1) SI2203187T1 (pt)
WO (1) WO2009053982A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658155B2 (en) 2010-12-27 2014-02-25 The Jackson Laboratory Compositions and methods relating to non-human animals modified to promote production of selected gametes
WO2016178233A1 (en) 2015-05-05 2016-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nucleic acid-cationic polymer compositions and methods of making and using the same
CN105039404A (zh) * 2015-06-25 2015-11-11 重庆高圣生物医药有限责任公司 一种靶向肿瘤的双调控重组腺相关病毒包装系统
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
US11974979B2 (en) 2022-01-29 2024-05-07 Resurge Therapeutics, Inc. Treatments for benign prostatic hyperplasia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108879A (en) 1994-03-07 2000-08-31 Yissum Res Dev Co Diagnostic assay for malignancies using the H19 gene and kit
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
US7041654B2 (en) * 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US6087164A (en) 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
WO2004024957A2 (en) 2002-09-12 2004-03-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for detection of micro-metastasis
AU2003291631A1 (en) 2002-10-03 2004-04-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for regulating expression genes
TW200613554A (en) * 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
ES2435774T3 (es) 2005-07-07 2013-12-23 Yissum Research Development Company, Of The Hebrew University Of Jerusalem Agentes de ácido nucleico para la regulación negativa de H19, y métodos de uso del mismo
JP2009508516A (ja) * 2005-09-22 2009-03-05 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム 核酸構築物、薬剤組成物、及び癌治療のためのその使用方法
WO2008087642A2 (en) 2007-01-16 2008-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid constructs and methods for specific silencing of h19
WO2008099396A1 (en) 2007-02-15 2008-08-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of h19-silencing nucleic acid agents for treating restenosis

Also Published As

Publication number Publication date
CA2703774A1 (en) 2009-04-30
ES2394129T3 (es) 2013-01-22
BRPI0818937A2 (pt) 2016-10-11
EP2203187B1 (en) 2012-08-29
US10004813B2 (en) 2018-06-26
RU2010119173A (ru) 2011-11-27
RU2487165C2 (ru) 2013-07-10
AU2008315409B2 (en) 2013-10-31
CY1113659T1 (el) 2016-06-22
WO2009053982A1 (en) 2009-04-30
EP2203187A1 (en) 2010-07-07
IL205048A (en) 2015-04-30
AU2008315409A1 (en) 2009-04-30
IL205048A0 (en) 2010-11-30
US9173964B2 (en) 2015-11-03
BRPI0818937B1 (pt) 2019-11-26
US20100256225A1 (en) 2010-10-07
KR20100100810A (ko) 2010-09-15
JP5486502B2 (ja) 2014-05-07
JP2011500080A (ja) 2011-01-06
CN101903046A (zh) 2010-12-01
KR101539796B1 (ko) 2015-07-27
US20160015834A1 (en) 2016-01-21
SI2203187T1 (sl) 2013-01-31
CN101903046B (zh) 2013-02-20
CA2703774C (en) 2019-05-21

Similar Documents

Publication Publication Date Title
D’Orazi et al. Mutant p53 and cellular stress pathways: A criminal alliance that promotes cancer progression
CY1121882T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
BR112012007137A2 (pt) metodos para modulacao da autofagia por meio da modulacao de produtos genicos inibidores da autofagia
AU2012340159A8 (en) RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
UY36404A (es) ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN
BR112015008708A2 (pt) composição para clivagem de dna alvo compreendendo um rna guia específico para o dna alvo e ácido nucleico que codifica proteína cas ou proteína cas e uso da mesma
BRPI0818937B8 (pt) constructos contendo múltiplos cassetes de expressão para terapia de câncer
CY1119491T1 (el) Συνθεσεις και μεθοδοι για την αναστολη της εκφρασης του γονιδιου alas1
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
CA2851316C (en) Genes and proteins for alkanoyl-coa synthesis
CU20120169A7 (es) Compuestos pirimidinílicos como inhibidores de la cinasa atr
BR112014030202A2 (pt) microorganismos e métodos para a produção de 4-hidroxibutirato 1,4-butanodiol e compostos relacionados
MX2013011922A (es) Compuestos de benceno substituido.
MX378277B (es) Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr).
MX2013010898A (es) Novedoso derivados de la pirimidina.
GEP20156347B (en) Benzodioxane inhibitors of leukotriene production
NZ707859A (en) Inhibitors of sodium glucose cotransporter 1
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
BR112012032248A2 (pt) composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
EP4438127A3 (en) Inhibiting ataxia telangiectasia and rad3-related protein (atr)
MX379585B (es) Composición para usarse en el tratamiento de cáncer que presenta pérdida hemicigota de tp53.
CY1113551T1 (el) Υποκατεστημενες ενωσεις νικοτιναμιδιου και η χρησιμοποιηση τους σε φαρμακα
GB201113880D0 (en) Novel compositions
HK1232228A1 (zh) 使 k-ras 静默之不对称干扰rna 组成物及其使用方法
WO2012033918A3 (en) Predicting responses to androgen deprivation therapy

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2641 DE 17-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.